Protara says TARA-002 posts 55% 12-month complete response in ADVANCED-2 trial

Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

TARA

0.00
  • Protara Therapeutics reported positive updated 12-month data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer; results were scheduled for presentation at American Urological Association 2026 Annual Meeting poster session.
  • Data showed durable responses over 12 months in responding patients, supporting continued development of TARA-002 as a bladder-sparing option in this setting.
  • Safety profile remained favorable, with no severe treatment-related adverse events reported and no treatment discontinuations tied to side effects.
  • Company kept plans to start ADVANCED-3, a registrational trial comparing TARA-002 with intravesical chemotherapy in BCG-naïve patients, in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150700PRIMZONEFULLFEED9720748) on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.